Health IT Analytics August 6, 2020
The study aims to bring advances in precision medicine to people living with rare cancers and their physicians.
TargetCancer Foundation (TCF) has announced the Target Rare Cancer Knowledge (TRACK) study, an initiative that leverages genomic analysis and precision medicine to provide patients and providers with personalized treatment recommendations.
TRACK aims to challenge the traditional method of clinical trial participation by incorporating remote consent, allowing patients to access genomic information and tailored treatment recommendations without the requirement of traveling to an academic medical center.
TargetCancer Foundation, a non-profit, patient-founded organization, will serve as the study sponsor and is collaborating with leading experts in the field of rare cancer care. The institution is also partnering with Foundation Medicine, a molecular information company.
...Today's Sponsors
Today's Sponsor